Company AxoGen, Inc.

Equities

AXGN

US05463X1063

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 04:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
6.52 USD -5.09% Intraday chart for AxoGen, Inc. -0.46% -4.54%

Business Summary

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its products include Avance nerve graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, Axotouch Two-Point Discriminator and Axoguard HA+ Nerve Protector. Avance nerve graft is a biologically active processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site. Axoguard Nerve Connector is a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce nerve reconstruction while preventing soft tissue attachment. Axotouch Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.

Number of employees: 427

Sales per Business

USD in Million2022Weight2023Weight Delta
Peripheral Nerve Regeneration and Repair
100.0 %
139 100.0 % 159 100.0 % +14.74%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
139 100.0 % 159 100.0 % +14.74%

Managers

Managers TitleAgeSince
Chief Executive Officer 62 06-04-30
Director of Finance/CFO 50 Dec. 05
Compliance Officer 57 23-03-05
Chief Tech/Sci/R&D Officer - 17-01-04
Director/Board Member 62 10-05-31
Corporate Officer/Principal - -
Sales & Marketing - 21-12-31
Sales & Marketing - 23-02-12
Corporate Officer/Principal 48 07-03-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 68 20-09-29
Director/Board Member 63 16-08-31
Director/Board Member 66 21-07-18
Director/Board Member 75 15-08-25
Chief Executive Officer 62 06-04-30
Director/Board Member 62 10-05-31
Director/Board Member 63 19-05-14
Director/Board Member 55 22-07-10
Director/Board Member 55 22-12-12
Director/Board Member 55 Dec. 19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 43,704,574 40,214,067 ( 92.01 %) 0 92.01 %

Shareholders

NameEquities%Valuation
ArrowMark Colorado Holdings LLC
11.92 %
5,152,300 11.92 % 42 M $
BlackRock Advisors LLC
7.224 %
3,121,203 7.224 % 25 M $
Morgan Stanley Investment Management, Inc.
7.134 %
3,082,437 7.134 % 25 M $
Soleus Capital Management LP
6.008 %
2,595,815 6.008 % 21 M $
Vanguard Fiduciary Trust Co.
5.706 %
2,465,496 5.706 % 20 M $
Millennium Management LLC
3.446 %
1,488,720 3.446 % 12 M $
1,143,788 2.647 % 9 M $
DAFNA Capital Management LLC
2.166 %
935,894 2.166 % 8 M $
Geode Capital Management LLC
2.075 %
896,336 2.075 % 7 M $
Perceptive Advisors LLC
1.871 %
808,380 1.871 % 7 M $

Company contact information

Axogen, Inc.

13631 Progress Boulevard Suite 400

32615, Alachua

+

http://www.axogeninc.com
address AxoGen, Inc.(AXGN)